Atp7B Gene is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes.
ATP7B is a copper-transporting P-type ATPase gene that plays a central role in systemic copper homeostasis and is the primary disease gene in Wilson's Disease.[1][2] ATP7B is highly expressed in hepatocytes, where it [2:1]
supports both copper incorporation into ceruloplasmin and biliary copper excretion. Pathogenic ATP7B variants reduce these functions and drive progressive copper overload with [3]
hepatic and neurologic toxicity.[1:1][3:1] [4]
The ATP7B gene is located on chromosome 13q14.3 and consists of 21 exons spanning approximately 80 kb of genomic DNA. The gene encodes a transmembrane protein of 1465 amino acids with a molecular weight of approximately 165 kDa. [5]
ATP7B belongs to the P-type ATPase family (E1-E2 ATPases) and contains several critical functional domains: [6]
ATP7B is predominantly expressed in: [7]
ATP7B operates through a sophisticated conformational cycle characteristic of P-type ATPases: [8]
Under physiologic copper conditions, ATP7B performs two essential functions: [9]
Cellular copper homeostasis requires specialized chaperone : [10]
Although ATP7B is classically considered a hepatology gene, its dysfunction has major neurologic consequences via systemic copper dysregulation. Copper spillover from hepatic
failure to maintain homeostasis contributes to deposition and injury in motor and cognitive circuits, especially in the basal ganglia. class="ref-link" data-ref-number="2" data-ref-text="Członkowska A et al., Wilson disease (2018)" title="Członkowska A et al., Wilson disease (2018)">2[6:1][7:1]
Copper accumulation in the brain leads to:
The basal ganglia are particularly vulnerable, especially:
This pattern can resemble Parkinson's Disease or other progressive neurologic conditions.[2:3]
Hundreds of ATP7B pathogenic variants have been reported worldwide, with substantial geographic heterogeneity:
| Variant | Type | Prevalence |
|---|---|---|
| H1069Q | Missense | Most common in European populations |
| R778L | Missense | Common in East Asian populations |
| A874V | Missense | Found in various populations |
| 2299insC | Frameshift | Common in some populations |
Variant class and residual transporter activity can influence age at onset and predominant phenotype, but clear one-to-one prediction remains limited.[2:4][4:1]
ATP7B molecular testing is now part of standard workups for suspected Wilson disease when biochemical findings are inconclusive or family screening is needed.[1:3][3:2]
MRI findings in neurologic Wilson disease include:[6:2][7:2]
Current disease management still relies on:
ATP7B is also a direct target for emerging disease-modifying approaches:
Preclinical studies in murine models have demonstrated:
The study of Atp7B Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
ATP7B is a member of the P-type ATPase family, one of the largest and most important families of membrane transport . These enzymes use the energy from ATP hydrolysis to transport ions across membranes, and their mechanism is highly conserved across species.
The E1-E2 Conformational Cycle:
E1 state: The protein is open to the cytoplasm with high affinity for copper ions. The N-terminal metal-binding domains (MBDs) sense intracellular copper concentration.
Copper binding: Six copper ions bind to the CXXC motifs in the N-terminal MBDs (MBD1-MBD6). Copper (Cu+) binds with high affinity through coordination with cysteine sulfurs.
ATP binding and phosphorylation: Copper binding triggers ATP binding to the A-domain, leading to phosphorylation of the P-domain (aspartate residue in the DKTGTLT motif).
Conformational transition: The protein transitions from the E1 to E2 conformation, exposing the copper-binding sites to the lumen side (trans-Golgi or extracellular space).
Copper release: The affinity for copper decreases dramatically in the E2 state, leading to copper release into the lumen.
Dephosphorylation: The A-domain hydrolyzes the phosphoenzyme intermediate, returning the protein to the E1 state.
This cycle allows ATP7B to transport copper against steep concentration gradients using energy from ATP hydrolysis.
The N-terminal region of ATP7B contains six copper-binding domains (MBD1-MBD6):
These domains function as both copper sensors and copper delivery systems. The binding of copper to these domains regulates the subcellular trafficking of ATP7B.
ATOX1 (Antisense Oxidoreductase 1) is the copper chaperone that delivers copper to ATP7B:
In Wilson disease, copper accumulation in the brain leads to neurodegeneration through multiple :
Oxidative stress:
Protein aggregation:
Excitotoxicity:
Advanced MRI techniques reveal characteristic patterns in Wilson disease:
T2-weighted MRI:
Susceptibility-weighted imaging (SWI):
Diffusion tensor imaging (DTI):
Wilson disease can present with parkinsonian features, leading to diagnostic confusion:
| Feature | Wilson Disease | Parkinson's Disease |
|---|---|---|
| Tremor | Wing-beating tremor | Resting tremor |
| Dystonia | Common | Less common |
| Kayser-Fleischer rings | Present in 90% | Absent |
| Ceruloplasmin | Low | Normal |
| MRI findings | Basal ganglia lesions | Nigral degeneration |
This overlap underscores the importance of considering copper metabolism in basal ganglia disorders.
Copper homeostasis is altered in Alzheimer's disease:
Aceruloplasminemia:
Menkes disease:
Penicillamine:
Trientine:
Tetrathiomolybdate:
Zinc salts block intestinal copper absorption:
Indications for transplantation:
Preclinical studies have shown promise:
Protein trans-splicing:
Small molecule correctors:
Copper chaperone modulators:
A newer biomarker with high specificity:
ATP7B sequencing is now widely available:
EASL-ERN, EASL-ERN Clinical Practice Guidelines on Wilson's Disease (2025). 2025. ↩︎ ↩︎ ↩︎ ↩︎
Członkowska A et al. Wilson disease (2018). 2018. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Alkhouri N et al. Wilson disease: a summary of the updated AASLD Practice Guidance (2023). 2023. ↩︎ ↩︎ ↩︎
Bull PC et al. The Wilson disease gene is a putative copper-transporting P-type ATPase similar to the Menkes gene (1993). 1993. ↩︎ ↩︎
Djebrani-Oussedik N et al. Relative exchangeable copper: A highly specific and sensitive biomarker for Wilson disease diagnosis (2025). 2025. ↩︎ ↩︎
Jing XZ et al. Neuroimaging Correlates with Clinical Severity in Wilson Disease: A Multiparametric Quantitative Brain MRI (2024). 2024. ↩︎ ↩︎ ↩︎
Su D et al. Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease: Insights From 7T Susceptibility-Weighted Imaging (2024). 2024. ↩︎ ↩︎ ↩︎
Padula A et al. Full-length ATP7B reconstituted through protein trans-splicing corrects Wilson disease in mice (2022). 2022. ↩︎ ↩︎
Murillo O et al. Long-term metabolic correction of Wilson's Disease in a murine model by gene therapy (2016). 2016. ↩︎ ↩︎ ↩︎
Murillo O et al. High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's Disease (2022). 2022. ↩︎ ↩︎